Disruption of Gpr45 causes reduced hypothalamic POMC expression and obesity.
Cui. Jing J; Ding. Yi Y; Chen. Shu S; Zhu. Xiaoqiang X; Wu. Yichen Y; Zhang. Mingliang M; Zhao. Yaxin Y; Li. Tong-Ruei R TR; Sun. Ling V LV; Zhao. Shimin S; Zhuang. Yuan Y; Jia. Weiping W; Xue. Lei L; Han. Min M; Xu. Tian T; Wu. Xiaohui X
Key Findings
- Loss of GPR45 in mice leads to early‑onset obesity and lower POMC expression
- GPR45 regulates POMC through the JAK/STAT signaling pathway
- Direct brain delivery of melanotan‑2 reverses obesity in Gpr45‑deficient mice
Practical Outcomes
- Melanotan‑2 can influence weight by acting on the POMC system, but the study used invasive brain injections, so it isn’t a ready‑to‑use protocol for people. It suggests that targeting the POMC pathway might help with weight control, but more research is needed to find safe, practical ways to use melanotan‑2 or similar compounds.
Summary
Scientists found that mice missing a brain protein called GPR45 become obese because they have less of a hormone that reduces appetite. Giving these mice a brain injection of melanotan‑2, which mimics that hormone, helped them lose weight. The study shows a link between GPR45, the appetite‑controlling hormone POMC, and obesity, but the treatment used is not practical for everyday use.
Abstract
A rise in the occurrence of obesity has driven exploration of its underlying genetic basis and potential targets for intervention. GWAS studies have identified obesity susceptibility pathways involving several neuropeptides that control energy homeostasis, suggesting that variations in the genes that regulate food intake and energy expenditure may contribute to obesity. In this study, we identified 5 additional obesity loci, including a neuronal orphan GPCR called Gpr45, in a forward genetic screen of mutant mice generated by piggyBac insertional mutagenesis. Disruption of Gpr45 led to increased adiposity at the time of weaning and increases in body mass, fat content, glucose intolerance, and hepatic steatosis with advancing age. Mice with disruptions in Gpr45 also displayed a reduction in expression of the metabolic regulator POMC and less energy expenditure prior to the onset of obesity. Mechanistically, we determined that GPR45 regulates POMC expression via the JAK/STAT pathway in a cell-autonomous manner. Consistent with this finding, intraventricular administration of melanotan-2, an analog of the POMC derivative α-MSH, suppressed adult obesity in Gpr45 mutants. These results reveal that GPR45 is a regulator of POMC signaling and energy expenditure, which suggests that it may be a potential intervention target to combat obesity.
Study Information
pubmed
2016
2016-08-08T00:00:00.000Z
10.1172/jci85676